*The search scope is limited to the products and news section of this site
The domestic oral anti-COVID-19 drug which was first approved for marketing by NMPA in China，continuously included in the national Diagnosis and Treatment Guidelines for COVID-19 and first included in China National Reimbursement Drug List
Products
First double-target nucleoside oral drug in the world to simultaneously target reverse transcriptase (RT) and viral infectivity factor (Vif) for the treatment of HIV infection
Products
Copyright © 2022 河南真实生物科技有限公司 All Rights Reserved 京ICP备2021026784号-1
